Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? - Wikidata - awgldk - TriplyDB

Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?

Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?

http://www.wikidata.org/entity/Q38139569

about

Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding Paraneoplastic Syndrome in Splenic Marginal Zone Lymphoma: A Rare Phenomenon of Paraplegia as an Atypical Presenting Manifestation Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges.Clinicopathological features of primary splenic follicular lymphoma.Surgical management of splenic marginal zone lymphoma.Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.

P2860

Q33586887-8987522D-4438-479C-A9F1-87A327C58CCB Q36932991-A3B5BB49-0538-451C-8435-043C6AD4D067 Q39347902-33033794-0AE1-43B2-9635-B526DF5ADE3C Q41925009-92BB9BA0-6E75-4252-B7C3-A2B0DE3988AF Q47771527-868F10D4-E830-464D-AF13-50E776144916 Q52599792-7165DA7D-DB80-4622-87AB-D926B6EC350E Q53550375-CC6A09DE-151D-41F9-BD1F-3A47C39DDA05

P2860

Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?

http://www.wikidata.org/entity/Q38139569

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?

@en

type

label

Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?

@en

prefLabel

Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?

@en

P1433

Q38139569-B223E026-C650-42D0-95CB-FB17DA7B19D9

P1476

Q38139569-3CE8C110-C971-42CE-94F6-A71DDFA3BB0A

P2093

Q38139569-13F31D57-6485-43B6-85D8-2AF0018C43E1

Q38139569-25DF15CD-D29D-4927-9B61-0BD92608991D

Q38139569-7209A29E-01E0-4119-A6EF-5EF56E351A3F

Q38139569-9CFC77FF-EDA1-48E4-9064-3BD334F1FE36

Q38139569-AE3A04E6-8BF8-4EE6-B7BF-F361BEA8D460

P2860

Q38139569-00378C5C-3E9D-436E-9509-AC86861E5137

Q38139569-113FE1F0-B88E-405A-A7B6-7B9E226FAF07

Q38139569-127048A2-F77D-4C18-A8A7-E56CDD383E51

Q38139569-26A4380B-209C-441F-84D9-68B27EFEB7C9

Q38139569-28A83806-FE51-4F26-9962-29DDFED8F7FB

Q38139569-33C22550-2464-41DF-914C-BA2BAB48C510

Q38139569-3572C3A6-731F-49A8-AED3-40B532D89C36

Q38139569-3F174964-D981-4037-9F7D-30E336DB824D

Q38139569-4A67C237-F5F4-4CE3-841C-E559D2A68351

Q38139569-4D53BEC2-BB67-40F7-8760-56050EBB8C6D

P304

Q38139569-F862BAE6-F843-4E8E-A200-136DD04EEC8D

P31

Q38139569-AED91046-D68A-4C54-97CC-76016758AF1E

P356

Q38139569-DCBD77DD-476B-426E-91D7-846321393DF7

P433

Q38139569-B454D5F8-A289-4E21-BCCC-E70ABFA769A1

P478

Q38139569-25BAF426-CC7D-45EE-85FF-52478C06FA31

P577

Q38139569-0D72DD35-9B33-4B34-A2C5-84562B17900B

P698

Q38139569-41E44299-9E40-4417-9E74-A12E22EF3B83

P356

10428194.2013.845884

P1433

Leukemia & Lymphoma

P1476

Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?

@en

P2093

Christina Kalpadakis

http://www.w3.org/2001/XMLSchema#string

Gerassimos A Pangalis

http://www.w3.org/2001/XMLSchema#string

Maria K Angelopoulou

http://www.w3.org/2001/XMLSchema#string

Sotirios Sachanas

http://www.w3.org/2001/XMLSchema#string

Theodoros P Vassilakopoulos

http://www.w3.org/2001/XMLSchema#string

P2860

Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma

Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.

Splenic marginal-zone lymphoma: a distinct clinical and pathological entity.

Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients.

Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients.

Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.

P304

1463-1470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2013.845884

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24050506

http://www.w3.org/2001/XMLSchema#string